---
title: "Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257276027.md"
description: "Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit"
datetime: "2025-09-15T01:43:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257276027.md)
  - [en](https://longbridge.com/en/news/257276027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257276027.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/257276027.md) | [繁體中文](https://longbridge.com/zh-HK/news/257276027.md)


# Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

### Related Stocks

- [JOINN (603127.CN)](https://longbridge.com/en/quote/603127.CN.md)
- [JOINN (06127.HK)](https://longbridge.com/en/quote/06127.HK.md)
- [NHWA (002262.CN)](https://longbridge.com/en/quote/002262.CN.md)
- [DEZHAN HEALTHCARE (000813.CN)](https://longbridge.com/en/quote/000813.CN.md)
- [Konruns (603590.CN)](https://longbridge.com/en/quote/603590.CN.md)
- [SHANGHAI YIZHONG (688091.CN)](https://longbridge.com/en/quote/688091.CN.md)
- [Porton (300363.CN)](https://longbridge.com/en/quote/300363.CN.md)

## Related News & Research

- [A full Strait of Hormuz blockage and 20% fall in supply could push oil over $100/bbl, Commerzbank says](https://longbridge.com/en/news/277608446.md)
- [Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter](https://longbridge.com/en/news/277631988.md)
- [SSY Group's Respiratory Drug Approved for Production in China](https://longbridge.com/en/news/277561555.md)
- [Cosco Shipping Energy Transportation responds to unusual share price moves](https://longbridge.com/en/news/277596582.md)
- [Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%](https://longbridge.com/en/news/277421361.md)